ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

ChatGPT flunks American College of Gastroenterology exams, Feinstein Institutes report

Researchers asked the artificial intelligence tool to take 2021 and 2022 multiple-choice self-assessment tests; results were published in the American Journal of Gastroenterology

While the popular artificial intelligence (AI) ChatGPT is seen as a potential educational tool, it won’t be getting its medical specialty certification anytime soon. To test its abilities and accuracy, investigators at The Feinstein Institutes for Medical Research asked the consumer-facing ChatGPT (Chat Generative Pre-trained Transformer, OpenAI) to take the 2021 and 2022 multiple-choice self-assessment tests for the American College of Gastroenterology. ChatGPT failed to make the grade, scoring 65.1 percent and 62.4 percent compared to the required 70 percent to pass the exams. Full details of the study were published today in the American Journal of Gastroenterology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230522005470/en/

Dr. Arvind Trindade is the senior author on the paper which published in the American Journal of Gastroenterology. (Photo: Business Wire)

Dr. Arvind Trindade is the senior author on the paper which published in the American Journal of Gastroenterology. (Photo: Business Wire)

ChatGPT is a 175-billion-parameter natural language processing model that generates human-like text in response to user prompts. The tool is a large language model (LLM) trained to predict word sequences based on context. ChatGPT has been tested before, even passing the United States Medical Licensing Exam. In this study, the Feinstein Institutes’ researchers wanted to challenge ChatGPT’s (versions 3 and 4) ability to pass the ACG assessment, which is supposed to gauge how one would fare on the actual American Board of Internal Medicine (ABIM) Gastroenterology board examination.

“Recently, there has been a lot of attention on ChatGPT and the use of AI across various industries. When it comes to medical education, there is a lack of research around this potential ground-breaking tool,” said Arvind Trindade, MD, associate professor at the Feinstein Institutes’ Institute of Heath System Science and senior author on the paper. “Based on our research, ChatGPT should not be used for medical education in gastroenterology at this time and has a ways to go before it should be implemented into the health care field.”

Each ACG test consists of 300 multiple-choice questions with real-time feedback. Each question and answer was copied and pasted directly into the ChatGPT versions 3 and 4. Overall, ChatGPT answered 455 questions (145 questions were excluded because of an image requirement). Chat GPT-3 answered 296 of 455 questions correctly (65.1 percent) across the two exams, and Chat GPT-4 answered 284 questions correctly (62.4 percent).

“ChatGPT has sparked enthusiasm, but with that enthusiasm comes skepticism around the accuracy and validity of AI’s current role in health care and education,” Andrew C. Yacht, MD, senior vice president, academic affairs and chief academic officer at Northwell Health. “Dr. Trindade’s fascinating study is a reminder that, at least for now, nothing beats hitting time-tested resources like books, journals and traditional studying to pass those all-important medical exams.”

ChatGPT does not have any intrinsic understanding of a topic or issue. Potential explanations for ChatGPT’s failing grade could be the lack of access to paid subscription medical journals or ChatGPT’s sourcing of questionable outdated or non-medical sources, with more research needed before it is used reliably.

About the Feinstein Institutes

The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health system science, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine. For more information about how we produce knowledge to cure disease, visit http://feinstein.northwell.edu and follow us on LinkedIn.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  222.56
+0.02 (0.01%)
AAPL  274.61
+0.50 (0.18%)
AMD  209.17
+1.59 (0.77%)
BAC  54.81
-0.52 (-0.94%)
GOOG  307.73
-1.59 (-0.51%)
META  657.15
+9.64 (1.49%)
MSFT  476.39
+1.57 (0.33%)
NVDA  177.72
+1.43 (0.81%)
ORCL  188.65
+3.73 (2.02%)
TSLA  489.88
+14.57 (3.07%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.